Gapping up
In reaction to strong earnings/guidance: SHLM +5.7%.
M&A news: QUNR 5.6% and CTRP 4.7% (Qunar in merger talks with CTRP, according to reports), JNY 0.3% (shareholders approve merger with Sycamore Partners at $15 per share).
Metals/mining stocks trading higher: NG +10.2% (continues to advance Donlin Gold as planned and maintains a 'strong' financial position), GOLD +2.8%, ABX +2.5%, AU +2.3%, GDX +1.8%, GG +1.8%, SLV +1.7%, EGO +1.5% (provides an update on its Deva Gold SA Certej project in Romania; Project will produce an average of 135,000 oz Au and 800,000 oz Ag per annum), RIO +1.3%, GLD +1.2%, VALE +1.1%.
Battery related names trading higher: PLUG +3.9% ( looking into new markets for fuel cells, according to reports), BLDP +2.8% KNDI +1.5% (China to increase promotion of 'new energy' cars, according to reports)
Other news: TLOG +5% (TetraLogic Pharmaceuticals Agrees to Acquire Shape Pharmaceuticals for $13 mln, future development and commercialization milestones, and tiered royalties on product sales), IDRA +4.4% (presents preclinical data showing IMO-8400 inhibits tumor growth and survival signaling in B-cell lymphoma cells with oncogenic MYD88 L265P mutation), JKS +3.9% (signs distribution agreement with Leading Solar Distributor in India; initiated with an Overweight at Barclays), MTSN +3.7% (light volume; still checking), NOK +3.3% (Nokia's plan to sell its Devices and Services business to Microsoft receives regulatory approval in China), ABMD +2.8% (received CE Marking approval in the European Union to market the Impella RP device), UL +2.4% (still checking), ZGNX +2% (files for injunction in Federal Court to block Massachusetts ban on Zohydro ER ), SNSS +2% (announces presentation of positive results from ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS), IMAX +1.9% (confirms it sold 20% stake in IMAX China to strategic Chinese investors for $80 mln), TWTR +1.8% (Turkish Prime Minister Tayyip Erdogan still wants TWTR banned, according to reports), BBRY +1.8% (BlackBerry wins patent infringement case), WUBA +1.5% (Tiger Global Investments reports 6.5% passive stake in 13G filing ), NVMI +1.4% (receives multiple orders for its advanced software solutions), MACK +1.4% (announced Phase 1 results from a clinical pilot study demonstrating that ferumoxytol was well tolerated when used as a tumor contrast agent prior to MM-398 treatment), CDE +1.1% (reports Q1 production of 4.1 mln ounces of silver and 58,836 ounces of gold; maintains 2014 production guidance), CLDX +0.6% (establishes preclinical proof of concept for new antibody drug conjugate CDX-014; Data presented at AACR 2014), AAL +0.6% (reports March traffic results)
Analyst comments: WFM +2.8% ( tgt raised to $70 from $62 at UBS; added to Key Call list), VIPS +2.8% ( upgraded to Outperform from Neutral at Credit Suisse), HE +2.3% ( upgraded to Outperform from Neutral at Macquarie), ARMH +2.1% (upgraded to Mkt Perform from Underperform at Bernstein), FEYE +0.9% ( upgraded to Outperform from Neutral at Wedbush; tgt lowered to $62 from $72 ), NKE +0.7% (upgraded to Buy from Hold at Stifel ), YELP +1.4% (Yelp upgraded to Buy from Neutral at SunTrust)